Get started
Author

Francesca Di Stefano

Observed names: Di Stefano, Francesca, F Di Stefano, F di Stefano, F. Di Stefano, Francesca Di Stefano, Francesca di Stefano
ORCID: 0000-0003-4545-2169
Observed ORCID: 0000-0003-4545-2169
OpenAlex ID: A5101890953
Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma
2000 · Justin S. Waters, Andrew Webb, et al. · Journal of Clinical Oncology · 457
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2009 · Florence I. Raynaud, Suzanne A. Eccles, et al. · Molecular Cancer Therapeutics · 278
PDF
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone
2000 · Paul A Clarke, Isabelle Hostein, et al. · Oncogene · 193
Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2.
1994 · T Hickish, D Robertson, et al. · PubMed · 71
Population Based Cancer Screening Programmes as a Teachable Moment for Primary Prevention Interventions. A Review of the Literature
2012 · Carlo Senore, Livia Giordano, et al. · Frontiers in Oncology · 70
PDF
Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements
2010 · Jonathan M. Large, Jane E. Torr, et al. · Bioorganic & Medicinal Chemistry · 24
Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo
2004 · P A Clarke, K E Pestell, et al. · British Journal of Cancer · 19
PDF
Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study
2025 · Alexandra Roux, Lucile Hervouet, et al. · BMC Cancer · 16
414A Pharmacological properties and in vitro and in vivo antitumour activity of the potent and selective PI3 kinase inhibitor PI103
2004 · P. Workman, F. Raynaud, et al. · European Journal of Cancer Supplements · 7
[Implementation of DNA-HPV primary screening in Italian cervical cancer screening programmes. Results of the MIDDIR Project].
2017 · Francesca Di Stefano, Paolo Giorgi Rossi, et al. · PubMed · 6
Correction: Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study
2025 · Alexandra Roux, Lucile Hervouet, et al. · BMC Cancer · 5
PDF
[Effective laws for tobacco control: EU directives and Italian legislation].
2006 · Lorena Charrier, Cristiano Piccinelli, et al. · PubMed · 2
Pharmacological properties of the PI3 kinase (PI3K) inhibitors PI-540 and PI-620
2008 · Florence I. Raynaud, Angela Hayes, et al. · Cancer Research · 1
568 POSTER In vitro and in vivo pharmacological properties of the potent phosphatidylinositol 3-kinase (P13K) family inhibitor Pl103
2006 · F. Raynaud, S. Eccles, et al. · European Journal of Cancer Supplements · 1
[A screening for all. How to make screening programmes more inclusive].
2023 · Gianluigi Ferrante, Francesca Di Stefano, et al. · PubMed
Supplementary Figure 1 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
Supplementary Figure 3A from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
PDF
Data from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
Supplementary Figure 2 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
Supplementary Table 1 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
Supplementary Figure 3C from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
PDF
Supplementary Figure 3B from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
PDF
Supplementary Figure 3B from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
Supplementary Figure 2 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
PDF
Supplementary Figure 1 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
PDF
Works count: 28
Citation count: 1,150
H-index: 8
I10-index: 8
Year
Topic
Type